Doprokin tablet 10mg #20

Form

tableti

Dosage mg

10

Pack

20

International Name - Domperidone Content: Each tablet contains: 10 mg Domperidone. Pharmacotherapeutic Group: Gastrointestinal motility regulator. Indication: Vomiting, nausea, complex of dyspeptic symptoms caused by delayed gastric emptying, gastroesophageal reflux, esophagitis (feeling of stomach fullness, belching, meteorism, heartburn). Vomiting, nausea of functional or organic genesis (including in infections, dietary disorders, chemical or radiation therapy). Vomiting and nausea caused by dopamine agonists in cases of their use in Parkinson's disease (such as Levodopa and Bromocriptine). Dosage regimen: In adults: In cases of acute vomiting or nausea, the drug is prescribed at 20 mg 3-4 times a day and before bedtime. In chronic dyspeptic events, the drug is prescribed at 10 mg 3 times a day and additionally before bedtime. If necessary, the mentioned dose is doubled. In children: In cases of acute vomiting or nausea, the drug is prescribed in the form of a suspension at 5 ml/10 kg of body weight, calculated for 3-4 doses per day and before bedtime. In chronic dyspeptic events, the drug is prescribed at 2.5 ml per 10 kg of body weight 3 times a day and, if necessary, additionally before bedtime. Note: Administration is recommended before meals. When taking the drug after meals, absorption is slightly slowed. Tablets are not prescribed for children under 5 years of age. In patients with renal insufficiency, it is recommended to reduce the frequency of drug administration (see section "Warnings and Precautions"). Contraindications: Hypersensitivity to the drug; Gastrointestinal bleeding; Mechanical intestinal obstruction or perforation. Prolactin-producing pituitary tumor (prolactinoma). Warnings and Precautions: When used with antacid or antisecretory drugs, the latter should be taken after meals, not before meals, i.e., they cannot be taken with Norpresdon. Use during lactation: Since the metabolic and hematoencephalic barrier is not fully developed in the first months of life, any drug in infants should be prescribed carefully and under strong medical supervision. Since the absence of neurological side effects is mainly due to weak crossing of the hematoencephalic barrier, neurological symptomatology cannot be completely excluded in children under 1 year of age. Use in liver diseases: Given the high metabolism of Domperidone in the liver, it should be prescribed carefully to patients with liver insufficiency. Use in kidney diseases: In patients with severe renal insufficiency (serum creatinine >6 mg/100 ml, i.e., > 0.6 mmol/l), the half-life of Domperidone increases from 7.4 to 20.8 hours, but plasma concentrations of the drug were lower than in healthy volunteers. Since a very small amount of the drug is excreted unchanged by the kidneys, there is almost no need to adjust the single dose in patients with renal insufficiency. When administered repeatedly, the frequency of administration should not exceed once or twice a day, depending on the severity of renal failure, and dose reduction may also be necessary. Usually, patients on long-term therapy should be under regular supervision. Pregnancy and lactation: Domperidone administered to animals at a dose of 160 mg/kg/day did not have a teratogenic effect. However, like most medications, Norpresdon is prescribed during the first trimester of pregnancy only if its therapeutic benefit is justified.